Her-2/neu and breast cancer

Diagnostic Molecular Pathology

Volumn 10, Issue 3, 2001, Pages 139-152

  Kaptain, Stamatina ^a   Tan, Lee K ^a   Chen, Beiyun ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast carcinoma; C erb B2; Her 2 neu; Herceptin; Trastuzumab

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; MONOCLONAL ANTIBODY; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CLINICAL TRIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HORMONE RESISTANCE; HUMAN; ONCOGENE C ERB; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; PROTO ONCOGENE; REVIEW;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; RECEPTOR, ERBB-2;

EID: 0034862192     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019606-200109000-00001     Document Type: Review

References (156)

1. The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity
2. Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma
3. Her-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
4. Prognostic and predictive factors in breast cancer by immunohistochemical analysis
5. Testing for erbB-2 by immunohistochemistry in breast cancer
6. Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer
7. Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer
8. Significance of c-erbB-2 amplification and DNA aneuploidy
9. Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior
10. The neu oncogene encodes an epidermal growth factor receptor-related protein
11. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma
12. Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
13. HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications
14. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer
15. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
16. Immunohistochemical assay of neu/c-erbB-2 oncogene product in paraffin-embedded tissues in early breast cancer: Retrospective follow-up study of 245 stage I and II cases
17. Gene diagnostics provide new insights into breast cancer prognosis and therapy
18. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
19. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading
20. Viability of immunohistochemical reactivity on stored paraffin slides
21. Prognostic significance of c-erbB-2 expression in node negative breast cancer
22. erbB2 amplification in breast cancer with a high rate of proliferation
23. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer
24. Her-2/neu amplification predicts poor survival in node-positive breast cancer
25. Analysis of cerbB2 expression using a panel of 6 commercially available antibodies
26. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
27. HER2 antibody for human cancer therapy
28. Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type 1 protein kinase A
29. Follow-up study of her-2/neu amplification in primary breast cancer
30. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have Her2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
31. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
32. c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients
33. The neu-protein and breast cancer
34. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells
35. Differences in breast cancer prognosis among African-American and Caucasian women
36. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo in vivo
37. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
38. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen
39. Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene
40. Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: An immunohistochemical study using monoclonal antibody NC1-CB11
41. Effects of adjuvant tamoxifen and of cytotoxic theraphy on mortality in early breast cancer
42. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 Randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
43. Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research
44. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study
45. The HercepTest assay: Another perspective
46. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product
47. Clinical highlights from the National Cancer Database, 1999
48. Human breast cancer: Prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features
49. Cancer statistics 2000
50. C-erbB-2 protein expression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes
51. The type 1 growth factor receptor family: New ligands and receptors and their role in breast cancer
52. Prognostic importance of c-erbB-2 expression in breast cancer
53. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease
54. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-Diamminedichloroplatinum against human breast and ovarian tumor cell lines
55. Evaluation of HER-2/neu (erbB-2) status in breast cancer: From bench to bedside
56. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol
57. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumor cell growth
58. Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful?
59. Amplification of the c-erb B-2 oncogene and prognosis of breast adenocarcinoma
60. The relationship between prognostic and predictive factors in the management of breast cancer
61. Amplified expression of the HER2/erbB2 oncogene induces resistance to tumor necrosis factor α in NIH 3T3 cells
62. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
63. HER2 causes transformation and tumorigenesis of NIH 3T3 cells
64. Basic science of HER-2/neu: A review
65. The biology of erbB-2/neu/HER-2 and its role in cancer
66. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer
67. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system
68. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement
69. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer
70. Automation of fluorescence in situ hybridization pretreatment: A comparative study of different sample types
71. neu/c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer
72. Expression of topoisomerase IIα is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer
73. Determination of Her-2/neu status in breast carcinoma: Comparative analysis of immunohistochemistry and fluorescent in situ hybridization
74. Her-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: Comparison of results and correlation with survival
75. c-erbB-2 immunostaining: Problems with interpretation
76. erbB-2 oncoprotein expression in breast carcinoma. Poor prognosis associated with high degree of cytoplasmic positivity using CB-11 antibody
77. Amplification of a novel v-erbB-related gene in a human mammary carcinoma
78. Cell biologic factors associated with the response of breast cancer to systemic treatment
79. Her-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization
80. MCF-7 breast cancer cells overepressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo
81. C-erbB-2 oncoprotein expression in primary and advanced breast cancer
82. Immunohistochemical assays for HER2 overexpression
83. Reproducibility of LSI Her-2/neu SpectrumOrange and CEP 17 SpectrumGreen dual color deoxyribonucleic acid probe kit
84. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials
85. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables
86. Global breast cancer mortality statistics
87. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer
88. Experts debate value of HER2 testing methods
89. Epidermal growth factor receptor (EGFR) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure
90. C-erbB-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer
91. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer
92. Routinely available indicators of prognosis in breast cancer
93. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
94. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer
95. Assessment of methods for tissue-based detection of the Her-2/neu alteration in human breast cancer: A direct comparison of fluorescence in sim hybridization and immunohistochemistry
96. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
97. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
98. HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
99. Her-2/neu as a predictive marker of response to breast cancer therapy
100. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity
101. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: Impact of fixation
102. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization
103. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: A multicenter portability study
104. HER-2 tyrosine knase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells
105. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
106. Overview of the biologic markers of breast cancer
107. Her-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
108. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues
109. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
110. Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease
111. The prognostic value of c-erbB2 in primary breast carcinomas: A study of 942 cases
112. The c-erbB-s proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers - A review
113. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines
114. Her-2/neu testing in breast carcinoma: A combined immunohistochemical and fluorescence in situ hybridization approach
115. c-erbB-2 amplification in node-negative human breast cancer
116. Increased HER2 with U.S. Food and Drug Administration-approved antibody
117. Immunohistochemical detection of HER-2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis
118. Her-2/neu (c-erb-B2) gene and protein in breast cancer
119. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
120. The Her-2/neu oncogene: Prognostic factor, predictive factor and target for therapy
121. Paclitaxel (Taxol)
122. Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor
123. The neu gene: An erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor
124. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by Her-2 immunophenotype and gene amplification
125. A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erb-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma
126. Clinical significance of Her-2/neu oncogene amplification in primary breast cancer
127. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer
128. Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
129. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts
130. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene
131. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers
132. Human breast cancer: Correlation of relapse and survival with amplification of the Her-2/neu oncogene
133. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
134. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
135. Topoisomerase I1α co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: Relationship to m-AMSA and mitoxantrone sensitivity
136. Mechanistic aspects of the opposing effects of monoclonal antibodies to the erbB2 receptor on tumor growth
137. Her-2/neu oncogene protein and prognosis in breast cancer
138. Chromogenic in situ hybridization A practical alternative for fluorescence in situ hybridization to detect Her-2/neu oncogene amplification in archival breast cancer samples
139. Cytoplasmic staining of c-erbB-2 is not associated with the presence of detectable c-erbB-2 mRNA in breast cancer specimens
140. Prognostic significance of her-2/neu oncoproden expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy
141. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
142. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up
143. Her-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis
144. Prognostic significance of Her-2 oncoprotein expression in breast cancer: A 30-year follow up
145. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of 176 cases
146. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message
147. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer
148. A scoring system for immunohistochemical staining: Consensus report of the task force for basic research of the EORTC-GCCG
149. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: Immunohistologic assessment correlates with gene amplification
150. The long-term prognostic significance of c-erbB-2 in primary breast cancer
151. Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer
152. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
153. Similarity of protein encoded by the human c-erB-2 gene to epidermal growth factor receptor
154. mdr-1 renders breast cancer cells highly resistant to taxol